"What we know for sure is [PSMA-PET is] just simply better imaging in terms of accuracy," says Ashley Ross, MD, PhD.
In this video, Ashley Ross, MD, PhD, associate professor of Urology and the clinical director of the Polsky Urologic Cancer Institute at Northwestern University, discusses the emergence of PSMA-PET in prostate cancer. Ross was speaking at the 2022 LUGPA Annual Meeting in Chicago, Illinois.
Lenvatinib plus pembrolizumab delays all organ tumor progression in advanced RCC
June 7th 2024“Overall, our results continue to support the use of lenvatinib and pembrolizumab as a current standard treatment option in the first-line treatment of [patients with] kidney cancer," says Viktor Grünwald, MD, PhD.
Pembrolizumab plus platinum-based therapy shows safety, efficacy in penile cancer
June 4th 2024“The HERCULES trial is the first trial to demonstrate the efficacy of immune checkpoint inhibitors in [patients with] advanced penile cancer with [a] manageable safety profile," says Fernando Cotait Maluf, MD.